U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07280572) titled 'RECLAIM Adaptive Platform Trial for PCC Treatments' on Dec. 01.
Brief Summary: RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC). The trial started in the Netherlands in February 2025, comparing metformin, colchicine and usual care in an open-label domain. The information in this registration concerns that first domain in the Netherlands. A second domain, comparing minocyclin to a matching placebo, is expected to start in January 2026, also in the Netherlands. Trial-arms, additional doma...